Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

James C Ulchaker 1
Melissa S Martinson 2
1 Department of Urology, Cleveland Clinic, Cleveland, OH; 2 Technomics Research, LLC, Minneapolis, MN, USA

Objective: To conduct a cost-effectiveness analysis from payers’ perspectives of six treatments for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and to examine positioning of these modalities in the marketplace for the best use of health care funds and quality-of-life benefits for patients.

Methods: The economic analysis was conducted with a Markov model to compare combination prescription drug therapy (ComboRx), minimally invasive therapies (MITs) including convective radiofrequency (RF) water vapor thermal therapy (Rezūm®), conductive RF thermal therapy (Prostiva®), and prostatic urethral lift (UroLift®), and invasive surgical procedures including photovaporization of the prostate (Greenlight® PVP) and transurethral resection of the prostate (TURP). Effects assessed with International Prostate Symptom Score, adverse events, and re-treatment rates were estimated from medical literature; treatments effects were modeled using a common baseline score. Starting with each therapy, patients’ transitions to more intensive therapies when symptoms returned were simulated in 6-month cycles over 2 years. Incremental cost-effectiveness ratios (ICERs) were calculated for pairs of treatments; uncertainty in ICERs was estimated with probabilistic sensitivity analyses.

Results: ComboRx was least effective and provided one-third of the symptom relief achieved with MITs. UroLift was similar in effectiveness to Prostiva and Rezūm but costs more than twice as much. The cheaper MITs were ~$900 more expensive than the cost of ComboRx generic drugs over 2 years. TURP and PVP provided slightly greater relief of LUTS than MITs at approximately twice the cost over 2 years; typically, they are reserved for treatment of more severe LUTS.

Conclusion: The analysis evaluated the costs and symptom relief of six treatment options in the continuum of care from a common baseline of LUTS severity. Identification of treatments for LUTS/BPH that demonstrate cost-effectiveness and provide appreciable symptom relief is paramount as reimbursement for patient care moves from volume-based services to value-based services.

Keywords: prostate, benign prostatic hyperplasia, lower urinary tract symptoms, cost-effectiveness analysis, minimally invasive therapy

Introduction

Benign prostatic hyperplasia (BPH) is very common with aging. It is a chronic condition often associated with a progressive development of voiding and obstructive lower urinary tract symptoms (LUTS). Nearly a third of all men develop LUTS, primarily from BPH; thus, due to high health care costs, BPH is included in the top ten prominent and costly diseases in men over 50 years of age in the US. The prevalence of LUTS/BPH, its impact on patients and their partners, and societal costs of this condition have been...
well described.2–4 While men less than 30 years of age have little evidence of BPH histology, the prevalence increases with each decade. BPH occurs in 50% of men 50–60 years of age, and in 90% of those older than 80 years.5,6 When LUTS become sufficiently bothersome and affect quality of life, men seek care from primary care physicians and urologists. Mild LUTS are typically managed with watchful waiting followed by drug therapy as the first line of treatment.7 The prevalence and progression of symptoms increase with advancing age,5,9 thereby necessitating consideration of alternative therapeutic modalities.

A 2015 population study estimates that 35.5 million men of age more than 30 years and 33.9 million men of age 40–79 years have at least mild urinary tract symptoms. Some studies indicate that only about a third of men with bothersome LUTS are aware of pharmacological agents or surgical interventions available to treat their condition. Even so, in 2015, it was estimated that 12.2 million men were actively managed for LUTS/BPH; this accounts for one of the largest segments of almost 25% of a urology practice.10,11 A decade ago, annual direct and indirect costs to the private sector related to BPH treatment in the US were estimated at $4 billion.12 The costs begin to accrue with men in their fourth decade as BPH is not only a disease of older men.

A perceptible change occurred in the management of LUTS/BPH after pharmacological agents became available. There was a significant decrease in the number of BPH surgical procedures. However, drug adherence rates are often low and may vary with class of drugs used.13,14 Lack of compliance is attributed to drug side effects, including sexual dysfunction, and lower-than-perceived expectations in the degree of improvement in symptoms and quality of life.14,15 Although patients may be prepared to wait longer periods of time for symptom relief with drugs in order to avoid surgery, drugs are expensive over long periods of time.16,17 Furthermore, compliance in some older patients is problematic. Men do not want to commit to lifetime drug therapy, often requiring multiple drugs for their chronic LUTS/BPH. The emergence of minimally invasive BPH treatments allows clinicians to tailor therapies in a continuum between medical management and more invasive surgical approaches as the condition progresses in severity.

The economic impact of treatment for BPH symptoms will continue to increase commensurate with the aging population. A report from the Centers for Disease Control and Prevention estimates that 20% of the population will be 65 years of age or older by 2030 and those 85 years and older will be the fastest growing segment of our population.18 While there are multiple options for treating BPH including medical, surgical, and newer minimally invasive therapies (MITs), the challenge related to costs to our society revolves around when to initiate, substitute, and/or advance to a more prostate tissue-targeted therapy after worsening of LUTS to achieve the best outcomes for patients. The purpose of this cost-effectiveness analysis is to examine critical positioning of treatments for LUTS/BPH in the marketplace and the best use of health care funds and quality-of-life benefits for the patient in the US.

The analysis estimated costs and effects of six therapies; the selected therapies are among those recommended in the American Urological Association (AUA) and European Association of Urology guidelines for the management of BPH.7,19 The National Institute of Diabetes and Digestive and Kidney Diseases subsequently convened a panel of key opinion leaders to develop a comprehensive strategic plan for advancing research in benign prostate disease including further development of intervention therapies based on non- or minimally invasive approaches.20

**Methods**

**Model-based cost comparison using clinical outcomes**

The economic model was structured using a Markov model programmed in TreeAge Pro 2016 (TreeAge Software, Inc.) as shown in Figure 1. Simulated patients started with a therapy and transitioned between follow-up and re-treatment if symptoms returned, in cycles with a length of 6 months. The base-case timeframe of 2 years was selected to encompass the limited posttreatment follow-up times of 2 years for some of the MITs included in the analysis. The authors acknowledge that longer-term results are important to all stakeholders, but for most BPH therapies, the short-term trends have been consistent with longer-term results.

The six therapies included:

- Therapy with combination prescription drugs (“ComboRx”), an inhibitor of 5α-reductase (e.g., dutasteride or finasteride), and an α-selective adrenergic receptor blocker (e.g., tamsulosin or doxazosin)
- The MITs of the following:
  - The Rezūm® System (a radiofrequency [RF] thermal therapy procedure)
  - The Prostiva® RF Therapy System (an RF thermal therapy procedure)
  - The UroLift® System (prostatic urethral lift, permanent implants to retract enlarged prostate tissue)
The invasive therapies of the following:
- Greenlight® laser photovaporization of the prostate (PVP)
- Transurethral resection of the prostate (TURP)

The simulated patients start with one of the treatments. Following treatment, the patients move through the model in 6-month cycles in which they could experience an adverse event (AE) requiring treatment, or return of significant BPH symptoms for which they would receive an additional therapy, or their experience could be uneventful, in which case they would incur only routine follow-up costs.

Common early- and late-occurring AEs whose treatment costs are significant were included in the model. Early AEs occurring within 6 months after treatment included: incontinence; de novo erectile dysfunction (ED), and stress/urge incontinence that is not self-resolving, urethral strictures, bladder neck contractures or stenosis, and urinary tract infections (UTIs). The non-resolving ED and some incontinence were assumed to be permanent and need chronic therapy. The late AEs, occurring 6 months or later after treatment, included acute urinary retention (AUR), incontinence, strictures, contractures, or stenosis, and UTIs. AUR was assumed to be due to either disease progression or a stenosis and treated accordingly.

In the model, when a patient’s symptoms return, the patient may be treated with a more invasive therapy in the following cycle. The treatment with increasingly more invasive therapies is intended to represent a continuum of care. For example, patients who initially received ComboRx and then have inadequate relief are treated with one of the three designated MITs (Rezūm, Prostiva, or UroLift) randomly chosen by the model in equal proportions. Afterward, they are modeled as MIT patients with regard to AEs and return of symptoms. Those patients who initially received an MIT and experience symptoms recurrence are retreated once with the same MIT, but then advance to an invasive surgical procedure (PVP or TURP, again randomly chosen by the model in equal proportions) when and if symptoms return a second time; afterward, they are modeled as invasive therapy/surgical patients. Patients who initially received PVP are treated with a second PVP; however with symptom progression, they advance to a TURP. Once a patient has a TURP, when additional treatment is required, another resection is performed. There is no mortality in the model because of the short time horizons analyzed.
We modeled the movement from less invasive to more invasive therapies because we wanted to understand if this overall strategy made sense clinically and financially. The cost of combination drugs (generic) over a year or 2 is lower than the cost of both RF thermal therapy procedures, which is lower than that of either invasive therapy procedure. Nonetheless, it is possible for AEs and repeated procedures to overwhelm up-front cost savings. To understand the total costs, we structured the model such that patients getting maximum medical therapy whose symptoms return get an MIT, and patients who have had MIT but whose symptoms return get a redo MIT procedure and then move on to an invasive procedure.

The model accumulates costs associated with each type of BPH therapy and treatments of AEs. Costs are derived from 2016 Medicare national average fee schedules for the BPH therapies including drugs, diagnostics, and procedures, and treatments for the AEs. References that contributed data on the frequency of revision procedures/treatments (re-treatment with same method or alternative treatment) or return of symptoms were used to calculate costs by using the time-discounted Medicare reimbursements as the cost each time a revision procedure occurred in the model. An analogous method was used for AEs and diagnostics. Drug payments were estimated from the 2014 Medicare Part D prescriber data for the combination drug therapy. For other drugs, such as those used in the treatment of incontinence, the Federal Upper Limit payments for 2016 set by the Affordable Care Act were used. Treatments for AEs included diagnostics, procedures, and drugs based on the advice of an advisory panel of three physicians: one advisor from an academic clinical practice and two advisors serving as medical directors in large health plans. Alternative treatments for a specific AE are weighted by their relative frequencies from the 2014 Medicare MEDPAR counts of procedures.21

Literature search methodology for data sources
To identify relevant citations, the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) database was searched for references in the English language from 2001 to June 2017. The search strategy included the Medical Subject Headings (MeSH) for the following: “Prostatic Hyperplasia” (MeSH) AND Benign or BPH, and each of the selected therapies (“combination drug therapy” or “polytherapy”; “prostatic urethral lift” or “UroLift”; “transurethral needle ablation” [TUNA, limited to Prostiva or Rezūm] or “Prostiva” [a transurethral, convectively delivered RF water vapor thermal therapy]; “photovaporization of the prostate” or PVP [limited to Greenlight or “Greenlight”; “transurethral resection of the prostate” or “TURP”). The search included primary research studies or case series published in peer-reviewed journals. Reviews and reports of single cases were excluded. Of the potentially relevant citations, 40 articles were selected and used to source data for this assessment.

The effectiveness of treatment was evaluated with the International Prostate Symptom Score (IPSS), a validated questionnaire for evaluating LUTS associated with BPH. The IPSS questionnaire is self-administered by the patient, comprising seven symptom questions (feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia, each referring to during the last month) and a quality-of-life item. Scores range from 0 (no symptoms) to 35 (most severe); a score of 8–19 indicates moderate LUTS, and 20–35 severe LUTS. The instrument is used to screen for, rapidly diagnose, and track the symptoms of, and suggest management of the LUTS due to BPH. The IPSS questionnaire is a standard instrument to assess treatment outcomes relative to baseline in most clinical trials.

Analytical procedures
Because the baseline IPSSs tended to be lower in patients treated with drugs than with procedures, the effectiveness of each treatment was estimated by calculating the weighted average annual change in IPSS relative to the baseline in the reference. Then, all patients were assigned the same baseline score in the model (IPSS of 22) to make the comparisons among therapies as fair as possible. The standard deviation (SD) of means from individual studies was used in the probabilistic sensitivity analysis.

The rate of early AEs was estimated by calculating weighted averages of the rates for 3 or 6 months as available. The rate of late AEs was estimated similarly at annual intervals and averaged over 1–2 years. The SD of rates of early and late AEs was used in the probabilistic sensitivity analysis.

Costs and cost-effectiveness were analyzed over 2 years from the perspective of the health care payer. Uncertainty was evaluated using a probabilistic sensitivity analysis in which IPSSs used normal distributions and rates per cycle used beta-binomial distributions. Each variable in the model was represented by values randomly chosen from the respective probability distribution. Costs and effects were discounted at 3%.

Cost-effectiveness was estimated by an incremental cost-effectiveness ratio (ICER) comparing two treatments at a
time. It is calculated using the difference in the average costs of each pair of treatments divided by the difference in their average effects (i.e., IPSS change from baseline with treatment A minus IPSS change from baseline with treatment B). In this study, the ICER represents the cost of each additional point decrease in the IPSS achieved by the more effective treatment (an IPSS decrease represents an improvement). If a treatment is both more effective and less costly when compared to another, it is defined as dominant to the other.

A probabilistic sensitivity analysis is intended to include most or all of the uncertainty about the parameters and the samples; thus, a traditional sensitivity analysis in which one or two parameters are varied at a time is unnecessary. The probabilistic sensitivity analysis in this study was run with 1,000 samples of the parameters and 100 individuals within each sample for a total of 100,000 simulations. Estimates of costs, effects, and ICERs were calculated using a probabilistic sensitivity analysis and graphed on the cost-effectiveness plane and in cost-effectiveness acceptability curves (CEACs).

Results
Estimates of effectiveness of treatments in cost-effectiveness analysis
Data were obtained from the literature to support a 2-year cost-effectiveness analysis. Weighted means were calculated from IPSSs, AE rates, and re-treatment rates reported in the papers. Estimates of effectiveness of each treatment (IPSS change), re-treatment rates, and probabilities of the occurrence of early and late AEs are shown for the six therapeutic modalities in Table 1.

The three MIT options resulted in similar degrees of relief of LUTS; in each, the mean IPSS decreased (improved) about 11 points at year 1 and were sustained at year 2. However, the UroLift procedure patients had a fivefold or greater rate of return of symptoms through year 2 (Table 1). The re-treatment rates for all treatments were estimated by the same methods: reported rates or number of events in the references were converted to a best-estimate time-to-event rate for each time period. Then, the rates were averaged over a 2-year period. This method assumes that the rate over 2 years is approximately constant.

The more invasive surgical options (Greenlight PVP and TURP) provided the greatest symptom relief; IPSS decreased a mean of nearly 16 points for both therapies at year 1, but relief diminished slightly to a 13-point reduction at year 2. Treatment with ComboRx resulted in appreciably less symptom relief over 2 years, and these patients had the highest rate (5.4%) of de novo ED. Greenlight PVP- and TURP-treated patients experienced a higher incidence of incontinence, stricture, contracture, or stenosis, and UTI than other modalities. The service components and fee schedules of the six therapies and treatment of AEs are shown in Table 2.

ICERs
The ICERs comparing pairs of therapies discounted at 3% over 2 years are shown in Table 3. The baseline IPSS of 22 was used for comparison of the therapies. Drug therapy, including ComboRx, is recommended as the first line of treatment for bothersome LUTS/BPH by AUA management guidelines. The generic ComboRx is the least expensive therapy but also the least effective. The branded ComboRx is the most expensive of all treatment options but has a similar low-effectiveness result as generic ComboRx.

At 2 years, after commencing ComboRx (generic or branded) treatment, the mean IPSS was about 19, only a 3-point improvement in symptom score, defined as a minimal but meaningful improvement. The two RF energy-generated thermal therapies, Prostiva and Rezūm, were similar; they were intermediate in costs and effects when compared to Greenlight PVP and TURP, which were very similar. Prostiva and Rezūm treatments reduced IPSS by 11 or 12 points compared to baseline. These IPSS reductions were about 25% less than TURP (16-point IPSS reduction); however, the ICERs were considerably higher for TURP and Greenlight PVP. The cost per additional point reduction in IPSS was $97 for Rezūm versus generic ComboRx and $686 for TURP versus Rezūm.

Cost-effectiveness simulations (ICERs) and probabilistic sensitivity analysis
The simulated ICERs for ComboRx, MITs, and invasive therapies are presented in Figure 2. These simulations include the probabilistic sensitivity analysis, so they include the uncertainty in the estimates of effects and rates. (The CEACs in Figure 3 summarize these probabilistic sensitivity analysis results.) The horizontal axis in the figures represents the difference in cost between two therapies, and the vertical axis the difference in effectiveness. When a fair proportion of simulated costs and effects are on both sides of the effectiveness-difference axis or the cost-difference axis, evidence for a meaningful difference between the treatments is weak. A comparison of the two RF thermal therapies, Rezūm and Prostiva, shows Rezūm to be slightly more expensive about 66% of the time and more effective about 97% of the time, indicating that the costs are unlikely to differ much, but offering strong evidence of a point difference in effectiveness.
Table 1 Estimates of effectiveness of treatment (IPSS improvements), durability of effects, and transition probabilities* for occurrence of early and late AEs

<table>
<thead>
<tr>
<th>Number of subjects included in effectiveness and safety assessments</th>
<th>Change in IPSS compared with baseline*</th>
<th>Return of LUTS (% patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Year 1</td>
</tr>
<tr>
<td>comboRx</td>
<td>2,524</td>
<td>2,403</td>
</tr>
<tr>
<td>rezum⁰</td>
<td>189</td>
<td>165</td>
</tr>
<tr>
<td>prostiva⁰</td>
<td>626</td>
<td>346</td>
</tr>
<tr>
<td>greenlight pvp</td>
<td>2,478</td>
<td>1,185</td>
</tr>
<tr>
<td>TURP</td>
<td>539</td>
<td>429</td>
</tr>
</tbody>
</table>

Notes: A decrease (minus sign) in IPSS represents an improvement compared with baseline. A common baseline IPSS of 22 was used for comparison of the treatment modalities in the model. For the modeling, it is assumed that ComboRx is the typical first line of treatment for LUTS/BPH. Patients who have inadequate symptom relief or worsening of LUTS may progress to one of the three MIT options (0.33 assumption). Patients who progress after an MIT have two surgical options (0.5 assumption). Early AEs are those occurring within 6 months after treatment, while late AE are those occurring more than 6 months later after treatment. *Per 6-month cycle. †First 6-month cycle. ‡When AE is not reported in any source, the rate is indicated as 0.01 for modeling purposes. Early rates in the few papers with reports were very high. From baseline reported in the individual papers.

Abbreviations: AE, adverse event; BPH, benign prostatic hyperplasia; ComboRx, combination prescription drug therapy; Greenlight PVP, photovaporization of the prostate; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; MIT, minimally invasive therapy; NA, not available; Prostiva, conductive radiofrequency thermal therapy; Ref., reference; Rezūm, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift, prostatic urethral lift.

(Figure 2A). However, the average point difference is not clinically meaningful, as it is less than 3 points.

Figure 2B compares UroLift and Rezūm (UroLift compared to Prostiva was similar). The UroLift procedure costs about $3,500 more than a Rezūm procedure on average. It is more expensive and less effective in 100% of the simulations; therefore, the Rezūm procedure dominates. Table 2 shows the service cost of approximately $6,400 over 2 years for UroLift.

Figure 2C compares the invasive therapies, TURP and Greenlight PVP. TURP is more expensive about 59% of the time and more effective about 73% of the time, indicating that these therapies are likely to be similar. Both TURP and Greenlight PVP are more costly but also provide a slightly greater relief of LUTS compared with Rezūm; average IPSS decrease by 13 points for the invasive therapies versus almost 12 points for Rezūm at 2 years (Figure 2D and E). The Rezūm therapy is more costly than generic ComboRx (the branded ComboRx is, however, more expensive), but in both simulations Rezūm is more effective (Figure 2F and G). The elongation of values in both figures is indicative of the great variability in effectiveness for ComboRx (generic and branded). This variability reflects variations in patients’ clinical condition, different responses and/or success of drug therapy to alleviate LUTS, and the significant lack of compliance to drug use within the first 2 years.

Figure 4 shows the average costs and effects of the six therapies. The x-axis represents IPSS changes from the common baseline of 22; lower scores (greater change from baseline) indicate a better response after treatment. The most efficient treatments, those that result in the greater symptom relief for the money spent, are found along the production possibility frontier, the line connecting the southeastern most treatments. The least expensive and least effective treatment ComboRx (generic) is found in the southwest corner. Moving
### Table 2 Service components of BPH diagnosis, treatments for LUTS, and adverse events

<table>
<thead>
<tr>
<th>Service</th>
<th>Cost (US$)/cycle</th>
<th>Included utilization</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiation of ComboRx therapy</td>
<td>$519</td>
<td>OV for diagnosis and titration</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for 2 single-pill tamsulosin/Flomax, finasteride/Proscar (90%) or 1 polytherapy dutasteride+tamsulosin/Jalyn (10%) pill</td>
<td>63,64</td>
</tr>
<tr>
<td>Ongoing ComboRx therapy</td>
<td>$394</td>
<td>OV for check-up (1 visit annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for 2 single-pill (90%) and 1 polytherapy (10%) pill</td>
<td>62</td>
</tr>
<tr>
<td>Rezūm™ procedure and related</td>
<td>$2,489</td>
<td>OV for diagnosis, post-procedure assessment, and check-up (1 visit annually)</td>
<td>62</td>
</tr>
<tr>
<td>Prostiva™ procedure and related</td>
<td>$2,489</td>
<td>Urodynamic study, cystoscopy, TRUS (50%), and TUNA</td>
<td>62</td>
</tr>
<tr>
<td>UroLift® procedure and related</td>
<td>$6,230</td>
<td>OV for diagnosis, post-procedure assessment, and check-up (1 visit annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urodynamic study, cystoscopy, TRUS (50%), and TUNA</td>
<td>62</td>
</tr>
<tr>
<td>Greenlight® PVP procedure and related</td>
<td>$4,661</td>
<td>OV for diagnosis, post-procedure assessment, and check-up (1 visit annually)</td>
<td>62</td>
</tr>
<tr>
<td>TURP procedure and related</td>
<td>$4,821</td>
<td>OV for diagnosis, post-procedure assessment, and check-up (1 visit annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urodynamic study, cystoscopy, TRUS (50%), and PVP</td>
<td>62</td>
</tr>
<tr>
<td>Dilatation for stricture, contracture, or stenosis</td>
<td>$665</td>
<td>OV for diagnosis and post-procedure assessment</td>
<td>62</td>
</tr>
<tr>
<td>Urethrotomy stricture, contracture, or stenosis</td>
<td>$1,926</td>
<td>Cystoscopy, dilation (filiform or dilator), and radiological supervision</td>
<td>62</td>
</tr>
<tr>
<td>TURBn for stricture, contracture, or stenosis</td>
<td>$2,892</td>
<td>OV for diagnosis and post-procedure assessment</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cystoscopy and TURBn</td>
<td>62</td>
</tr>
<tr>
<td>Initiation of Rx therapy for erectile dysfunction</td>
<td>$155</td>
<td>OV for diagnosis and titration</td>
<td>62</td>
</tr>
<tr>
<td>Ongoing Rx therapy for erectile dysfunction</td>
<td>$31</td>
<td>OV for check-up (1 annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for erectile dysfunction</td>
<td>62</td>
</tr>
<tr>
<td>Initiation of injections for erectile dysfunction</td>
<td>$399</td>
<td>OV for diagnosis and assessment</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injections in-office</td>
<td>62</td>
</tr>
<tr>
<td>Ongoing injections for erectile dysfunction</td>
<td>$66</td>
<td>OV for check-up (1 annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for self-injections (33% each branded Caverject, generic PEG-1, and generic Tri-mix)</td>
<td>65</td>
</tr>
<tr>
<td>Initiation of Rx therapy for incontinence</td>
<td>$579</td>
<td>OV for diagnosis and titration</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for incontinence (33% each branded Vesicare, generic oxybutynin, and generic tolterodine)</td>
<td>66,67</td>
</tr>
<tr>
<td>Ongoing Rx therapy for incontinence</td>
<td>$454</td>
<td>OV for check-up (1 annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for incontinence</td>
<td>62</td>
</tr>
<tr>
<td>Initiation of PTNS therapy for incontinence</td>
<td>$2,007</td>
<td>OV for diagnosis and 12 weekly treatments</td>
<td>62</td>
</tr>
<tr>
<td>Ongoing PTNS therapy for incontinence</td>
<td>$795</td>
<td>OV's monthly for maintenance therapy</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OV's monthly for maintenance therapy</td>
<td>62</td>
</tr>
<tr>
<td>Initiation of Botox therapy for incontinence</td>
<td>$1,798</td>
<td>OV's for diagnosis and assessment</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cystourethroscopy, with injection(s) for chemo-denervation</td>
<td>62</td>
</tr>
<tr>
<td>Ongoing Botox therapy for incontinence</td>
<td>$1,703</td>
<td>Injections for maintenance of chemo-denervation</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OV for check-up (1 annually)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injections for maintenance of chemo-denervation</td>
<td>62</td>
</tr>
<tr>
<td>AUS procedure for incontinence</td>
<td>$1,239</td>
<td>OV's for diagnosis and assessment</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cystoscopy, urodynamic study, and AUS procedure</td>
<td>62</td>
</tr>
<tr>
<td>Rx for urinary tract infection</td>
<td>$127</td>
<td>OV for diagnosis and check-up</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rx for urinary tract infection (16% each branded Monurol, generic trimethoprim/sulfamethoxazole, nitrofurantoin, ciprofloxacin, levofloxacin, and cepalexin)</td>
<td>66–69</td>
</tr>
<tr>
<td>Temporary therapy for acute urinary retention</td>
<td>$145</td>
<td>OV for diagnosis</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cystoscopy and insertion of bladder catheter</td>
<td>62</td>
</tr>
</tbody>
</table>

**Abbreviations:**  
AUS, artificial urinary sphincter; BPH, benign prostatic hyperplasia; ComboRx, combination prescription drug therapy; Greenlight PVP (or PVP), photovaporization of the prostate; LUTS, lower urinary tract symptoms; OV, office visit; PEG-1, prostaglandin-1; Prostiva, conductive radiofrequency thermal therapy; PTNS, percutaneous tibial nerve stimulation; PUL (or Urolift), prostatic urethral lift; Rezūm, convective radiofrequency water vapor thermal therapy; Rx, prescription; Tri-mix, alprostadil, papaverine, and phentolamine; TRUS, transrectal ultrasound; TUNA, transurethral needle ablation; TURBn, transurethral resection of the bladder neck; TURP, transrectal resection of the prostate.
Table 3 Costs, effectiveness, and ICERs of the treatments over a 2-year horizon

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Statistic</th>
<th>ComboRx Medicare Part D price</th>
<th>Branded price</th>
<th>Rezūm®</th>
<th>UroLift®</th>
<th>Prostiva®</th>
<th>Greenlight®</th>
<th>TURP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>Mean at 2 years</td>
<td>$1,736</td>
<td>$7,082</td>
<td>$2,582</td>
<td>$6,386</td>
<td>$2,855</td>
<td>$5,099</td>
<td>$5,181</td>
</tr>
<tr>
<td>IPSS</td>
<td>Mean at 2 years</td>
<td>18.9</td>
<td>18.9</td>
<td>10.2</td>
<td>11.4</td>
<td>10.9</td>
<td>7.4</td>
<td>6.4</td>
</tr>
<tr>
<td>Cost-effectiveness of IPSS at 2 years</td>
<td>$97</td>
<td>$-518</td>
<td>Base comparator</td>
<td>$-3,058</td>
<td>$-3,52</td>
<td>$900</td>
<td>$686</td>
<td></td>
</tr>
<tr>
<td>Rezūm versus other*</td>
<td>Dominated</td>
<td>No</td>
<td>Yes</td>
<td>NA</td>
<td>Yes</td>
<td>Yes*</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Cost-effectiveness of IPSS at 2 years</td>
<td>$276</td>
<td>$-1,523</td>
<td>$6,863</td>
<td>$-240</td>
<td>$509</td>
<td>$83</td>
<td>Base comparator</td>
<td></td>
</tr>
<tr>
<td>TURP versus other*</td>
<td>Dominated</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Notes: “Dominated” indicates a treatment that is more expensive and less effective than another is dominated by the other. ICER: cost per additional point reduction (in IPSS) provided by the more expensive treatment. Bolded, negative numbers indicate higher cost. Over 2-year time horizon with both costs and effects discounted at 3% annually. The mean IPSS and costs indicate dominance, but the effectiveness and costs are not dissimilar when uncertainty is considered. Costs based on US$.*

**Abbreviations:** ComboRx, combination prescription drug therapy; Greenlight PVP, photovaporization of the prostate; iCER, incremental cost-effectiveness ratio; IPSS, International Prostate Symptom Score; NA, not applicable; Prostiva, conductive radiofrequency thermal therapy; Rezūm, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift, prostatic urethral lift.

north and east as costs and effects increase, Rezūm and Prostiva form the next frontier therapies. Greenlight PVP and TURP lie at the northeastern most point on the frontier as they are the most effective, but also the most costly.

The ICERs for ComboRx versus Rezūm and Rezūm versus TURP are represented by the slopes of the lines connecting generic ComboRx to Rezūm and Rezūm to TURP. The treatments along the curve connecting ComboRx (generic), Rezūm, and TURP are the most effective for the cost. Therapies that are inside this frontier are less effective and more costly (i.e., dominated by therapies on the frontier). (Note that there is an ICER for any two treatments, but only two of the ICERs, those on the production possibility frontier, are shown in Figure 4.)

CEACs

The CEACs shown in Figure 3 plot the probability that the more expensive therapy is cost-effective versus the maximum acceptable ICER. These plots summarize the probabilistic sensitivity analysis results shown in Figure 2. The comparisons include those therapies on the production possibility frontier: Rezūm versus generic ComboRx and TURP versus Rezūm. With the 1,000 simulated ICERs, Rezūm is always more expensive than generic ComboRx. Therefore, the 10% of ICERs that are negative is the result of instances in which ComboRx is more effective than Rezūm. The probabilistic sensitivity analysis indicates that 95% of the time, the cost per additional IPSS point reduction is less than $150 over 2 years when Rezūm is used instead of ComboRx (Figure 3A). For 95% of the time, the cost per point reduction is less than $250 over 2 years when TURP is used instead of Rezūm (Figure 3B).

Discussion

The cost-effectiveness analysis in this report is inclusive of a spectrum of therapies used for the management of LUTS/BPH. It is important to understand the trends in utilization that impact the treatment patterns for BPH and the consequent cost-effectiveness. While medical therapy is a common first-line treatment option for mild-to-moderate voiding symptoms, TURP had been the main form of BPH surgical treatment for many years and remained a standard for improvements in urinary function to which other therapies were compared. Both pharmacological and technical interventions for BPH have continued to evolve as clinicians learn more about the disease. The thermal therapies (transurethral microwave thermotherapy [microwave-generated] and TUNA [RF-generated conductive heating; e.g., Prostiva]) and laser procedures (e.g., Greenlight PVP) as less morbid alternatives to TURP were associated with significant revival of interest in BPH interventions. Laser procedures have similar efficacy in symptom relief to TURP. As reported in several sources, the consequence of the newer therapeutic options was a steady decline in TURP procedures while laser vaporization increased steadily. PVP serves as an alternative to TURP as TURP may be associated with perioperative morbidities directly related to prostate volume and surgically high-risk patients with associated comorbidity, including pacemakers, and anticoagulant and platelet anti-aggregate medications. TURP and Greenlight PVP remain the most costly alternatives today and typically are reserved for treatment of moderate-to-severe LUTS or larger prostates. While they among the most cost-effective treatments for relief of symptoms as shown in Figure 4, the rates of AEs, including incontinence, UTI, AUR, and bladder neck contracture, for these surgical procedures are significant, again contributing to more discomfort for the patients and costs to payers.

The emergence of the newer MITs, first the UroLift as a permanent implant for mechanical lifting of prostate tissue (FDA clearance 2013), and the Rezūm System convective RF
Figure 2 Cost-effectiveness simulations of minimally invasive and invasive therapies.

Notes: In 1000 simulated samples of size 100, these figures plot the differences in costs paired with the differences in effectiveness (improvements in IPSS) between two treatments. (A) Prostiva vs Rezūm, (B) UroLift vs Rezūm, (C) TURP vs Greenlight PVP, (D) TURP vs Rezūm, (E) Greenlight PVP vs Rezūm, (F) Rezūm vs ComboRx (generic), and (G) ComboRx (branded) vs Rezūm.

Abbreviations: ComboRx, combination prescription drug therapy; Greenlight® PVP, photovaporization of the prostate; IPSS, International Prostate Symptom Score; Prostiva®, conductive radiofrequency thermal therapy; Rezūm®, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift®, prostatic urethral lift.
Figure 3 Cost-effectiveness (US$) acceptability curves for (A) Rezūm® versus ComboRx and (B) TURP versus Rezūm. ICER: cost per additional point reduction (in IPSS) provided by the more expensive treatment.

Abbreviations: ComboRx, combination prescription drug therapy; iCER, incremental cost-effectiveness ratio; iPSS, International Prostate Symptom Score; Rezūm, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate.

Figure 4 Production possibility frontier graph for average costs of the six therapies relative to cost-effectiveness over 2 years.

Note: The x-axis represents mean iPSS changes from the common baseline.

Abbreviations: ComboRx, combination prescription drug therapy; Greenlight® PVP, photovaporization of the prostate; iPSS, International Prostate Symptom Score; Prostiva®, conductive radiofrequency thermal therapy; Rezūm®, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift®, prostatic urethral lift.
thermal therapy (FDA clearance 2015) that followed 2 years later, has given rise to therapies that provide durable relief of urinary symptoms over at least 2 years of follow-up with IPSS improvements nearly approaching those of TURP and Greenlight PVP for patients with moderate-to-severe LUTS/BPH. When the requirement for general anesthesia for Greenlight PVP and TURP is considered, the costs for these surgical procedures exclusive of the medical devices are higher than for either MIT. Both UroLift and Rezūm have been evaluated in rigorously controlled (sham procedure controls) clinical trials with strict inclusion and exclusion criteria performed by accomplished clinicians. The effectiveness of these two MITs is supported by selective evidence-based studies. Currently, these technologies serve as options in the continuum between medical management and surgical approaches due to demonstrated tolerability, safety and effectiveness, and cost savings. However, this study has shown that Rezūm is much less expensive and might be a preferred choice in a health care system seeking to contain costs.

The clinical reports for the earlier TUNA technology (Prostiva) predate 2003. This MIT has been evaluated in randomized comparative studies versus TURP in 25–65 patients, although not in sham-controlled studies.\textsuperscript{34,55,77} Traditional RF thermotherapy with a TUNA system, the Prostiva system, has had little change in utilization from 2000 to 2008 possibly as a consequence of being overshadowed by aggressive marketing of laser vaporization.\textsuperscript{78} The Rezūm System utilizes the convective delivery of stored thermal energy via steam water vapor created with RF electromagnetic energy, rather than the application of RF energy directly to prostate tissue with the Prostiva System which relies on the conductive delivery of heat thermal energy through the tissue. Thus, ablative RF thermal energy convectively delivered with the Rezūm System is confined within the prostatic capsule and prevents the conduction of harmful levels of electromagnetic energy outside the intended treatment areas, which could result in collateral tissue damage. The convective delivery of “wet” RF thermal energy into the prostate by the Rezūm System preserves the prostatic urethra, while also avoiding adverse clinical effects such as tissue carbonization, charring, or tissue desiccation that can result from the application of RF energy directly to prostate tissue with the Prostiva System.\textsuperscript{78}

The production possibility frontier is anchored by TURP/Greenlight PVP and pharmaceuticals that have been available for years (Figure 4). The UroLift procedure falls between the two anchors, but the newly established reimbursement framework has pulled the cost-effectiveness line substantially northward for this MIT leaving Prostiva and Rezūm as therapeutic options at a lower cost and with a similar effectiveness (Table 1). The ICER for UroLift versus Rezūm is negative (approximately $3,000) because UroLift costs more and provides slightly less relief than Rezūm (although not a clinically significant amount) for each incremental improvement in urinary symptom relief compared with Rezūm. Thus, the model estimates that on average Rezūm ranks favorably among the MITs; UroLift is the most expensive. Rezūm has been shown to provide consistent and durable improvements in LUTS throughout 2 years of follow-up,\textsuperscript{26,78,79} and has a substantially lower rate for return of symptoms (Table 1). The re-treatment rate for Rezūm is about 4% over 2 years\textsuperscript{26} compared with about 7.5% for UroLift.\textsuperscript{28}

Evaluation of ComboRx on the production possibility frontier (Figure 4) and ICERs (Table 3) shows a therapy that is the most expensive for branded drugs, least expensive for generic drugs, and the least effective for both generic and branded ComboRx. Medications for treatment of BPH do not provide immediate gratification for the patients as they may take up to 2 years of continuous use to obtain maximum benefit. Furthermore, whether due to AEs or dissatisfaction with medications, patients often interrupt therapy — stopping and restarting, changing prescriptions, or discontinuing completely.\textsuperscript{14,80} The rate of discontinuation after 12 months of medication therapy ranges from 62 to 91%.\textsuperscript{14,80,81}

As shown in clinical studies evaluated in this report, the maximum urinary symptom relief attained with ComboRx is only about 50% as effective as any MIT procedure; in this study, they were about one-third as effective. Thus, there is a good argument to be made that given the substantial cost-effectiveness evidence of MITs to treat LUTS/BPH, MITs could be considered as the first line of treatment compared to the low effectiveness of generic and branded agents in place of ComboRx if the 2-year results continue over 4 or more years. The additional 2-year costs would be justified based on the higher effectiveness, and over as little as 4 years, the total costs of ComboRx may exceed those of the MITs. Among the MITs, the Rezūm System warrants consideration as a first-line treatment choice for the earlier management of LUTS/BPH. It has both a favorable cost-effectiveness and excellent safety/tolerability profile relative to UroLift and Prostiva, and circumvents the need for long-term use. It does not have the unpredictability of outcomes associated with ComboRx. As value- and quality-based payment programs continue to evolve, technologies that demonstrate cost-effectiveness and provide good outcomes will continue to move to the forefront and provide benefit to physicians and patients.\textsuperscript{82}
The authors recognize several limitations of the study. BPH and associated LUTS is a condition affecting quality of life with varying incidence and degrees of severity among the spectrum of the seven typical symptoms compounded by the dynamics of aging in the patient. Thus, the analysis is not confined to a hypothetical patient with LUTS/BPH from whom we can draw overall conclusions. Rather, the sample of patients assessed is heterogeneous; the analysis represents the continuum of care that a patient may experience based on variables such as degree of symptom bother, tolerance, prostate size or comorbidities, and therapeutics available to them. We have utilized the treatment experiences of published reports realizing that clinical outcomes for the new MIT procedures have been derived from smaller numbers of patients and shorter durations of follow-up evaluations. This is in contrast to follow-up for large numbers of patients receiving drug therapy and invasive surgical procedures, which have been in use as treatment options for over a decade.

Conclusion
This cost-effectiveness analysis of the treatment options for the disease pathway of the severities of LUTS due to BPH was conducted in the context of currently available therapeutic options. On one end of the spectrum are generic ComboRx medications, the typical initial treatment option for bothersome LUTS. The medication option is the least expensive but not cost-effective as this modality requires extended use to barely achieve half the urinary symptom improvements obtained through minimally invasive procedures. At the other end of the spectrum, a surgical intervention such as TURP has the highest procedural cost but requires more stringent criteria for use. TURP is typically reserved for patients with obstructive prostatic hypertrophy in whom medical management and less-invasive prostatic surgical procedures have failed, or who have large prostates or an unusual shape that could include an enlarged median lobe or significant intravesical prostatic encroachment. Both Greenlight PVP and TURP provide similar and greater symptom relief; however, these options also demonstrate higher rates of AEs and increased procedure time, and potentially require general/spinal anesthesia, adding additional costs to the payer. The MITs including the two RF thermal therapies Prostiva and Rezūm, and the UroLift procedure may be viewed as intermediate interventions and more effective than medications for BPH, although not as effective as TURP or PVP. They can be performed as outpatient or same-day procedures and are less costly overall. UroLift was the most expensive of the MITs. Evidence-based evaluations support Rezūm as a cost- and clinically effective treatment for BPH, given the urinary symptom score improvements, markedly improved from baseline and throughout 2 years, and minimal transient perioperative side effects. As such, Rezūm warrants consideration as a first-line therapeutic alternative to medical therapy in men seeking treatment for bothersome moderate-to-severe symptoms of BPH, including those with median lobe hyperplasia. Evaluation of the cost-effectiveness of treatments of LUTS/BPH that improve patients’ quality of life is both relevant to clinicians seeking expedient and cost-conscious therapies and to payers’ reimbursement plans driven (or necessitated) by value-based medical care.

Acknowledgments
This study was supported by NxThera, Inc., Maple Grove, MN, USA. The study results have not been contingent on the sponsor’s approval nor has the sponsor been involved in censorship of the report.

Disclosure
Dr. Ulchaker participated as a clinical investigator in the pivotal trial of the convective RF water vapor thermal therapy. Dr. Martinson of Technomics Research was contracted to perform the cost-effectiveness analysis. The authors report no other conflicts of interest in this work.

References
Cost-effectiveness analysis of BPH treatments


